CU Cancer Center member Manali Kamdar, MD, clinical director of lymphoma services, explores sequencing options for third-line relapsed/refractory large B-cell lymphoma (LBCL). She highlights the curative potential of liso-cel and the convenience of CD20 BiTEs, offering insights into their respective benefits and challenges.